Inovio Pharmaceuticals (NASDAQ:INO) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Inovio Pharmaceuticals (NASDAQ:INO) from a sell rating to a hold rating in a report published on Saturday morning.

Several other brokerages have also recently issued reports on INO. Piper Sandler reaffirmed an “overweight” rating and set a $6.00 target price (up from $5.00) on shares of Inovio Pharmaceuticals in a research report on Friday, November 14th. Oppenheimer restated an “outperform” rating on shares of Inovio Pharmaceuticals in a research note on Friday. HC Wainwright reaffirmed a “neutral” rating on shares of Inovio Pharmaceuticals in a research report on Tuesday, December 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a research note on Monday, December 29th. Finally, UBS Group reiterated an “overweight” rating on shares of Inovio Pharmaceuticals in a report on Friday, November 14th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Inovio Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $6.75.

Inovio Pharmaceuticals Price Performance

NASDAQ:INO opened at $1.66 on Friday. The company has a 50-day moving average of $1.65 and a 200 day moving average of $2.05. Inovio Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $2.98. The firm has a market cap of $110.77 million, a PE ratio of -0.99 and a beta of 1.70.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings data on Thursday, March 12th. The biopharmaceutical company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.68. The business had revenue of ($0.07) million for the quarter, compared to the consensus estimate of $0.33 million. Sell-side analysts anticipate that Inovio Pharmaceuticals will post -4.23 EPS for the current fiscal year.

Institutional Trading of Inovio Pharmaceuticals

A number of institutional investors have recently made changes to their positions in INO. MCF Advisors LLC purchased a new position in Inovio Pharmaceuticals during the 3rd quarter worth $26,000. SG Americas Securities LLC purchased a new stake in Inovio Pharmaceuticals in the third quarter valued at about $27,000. Stephens Inc. AR purchased a new stake in Inovio Pharmaceuticals in the third quarter valued at about $32,000. Focus Partners Wealth acquired a new stake in Inovio Pharmaceuticals in the third quarter worth about $33,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Inovio Pharmaceuticals by 39.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 5,894 shares in the last quarter. Institutional investors and hedge funds own 26.79% of the company’s stock.

Key Stories Impacting Inovio Pharmaceuticals

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: BLA accepted under the FDA’s Accelerated Approval Program for INO‑3107 (potential RRP treatment); PDUFA date set for Oct. 30, 2026 — a clear regulatory milestone that could materially de‑risk and create commercial value if approved. INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Q4 2025 results showed a surprising EPS beat (reported $0.31 vs. consensus ~($0.37)), which reduces short‑term earnings uncertainty. The company also highlighted published clinical/immunology data and advancing next‑generation DNA medicine technologies (DMAbs, DPROT). INOVIO Reports Fourth Quarter and Full Year 2025
• Neutral Sentiment: Management discussed strategic moves and regulatory planning on the Q4 earnings call; investors should listen for commercialization plans, cash‑burn guidance, and timelines for INO‑3107 ahead of the October PDUFA. Earnings Call Highlights
• Negative Sentiment: Multiple law firms have filed or are soliciting lead‑plaintiff actions alleging securities fraud for the Oct. 10, 2023–Dec. 26, 2025 class period; several reminders cite an April 7, 2026 deadline — this legal overhang increases litigation risk, potential settlement exposure, and headline volatility. Representative notices: Glancy Prongay Wolke & Rotter and Schall Law Firm. Deadline Alert: Glancy Prongay Wolke & Rotter Schall Law Firm Notice
• Negative Sentiment: Revenue metrics missed expectations (press coverage shows revenue below consensus), and sell‑side models still forecast a negative FY EPS (analyst consensus cited ~‑4.23), implying continued cash‑flow and financing risk that could dilute shareholders. MarketBeat INO snapshot
• Negative Sentiment: Technical/market context: the 50‑day moving average sits below the 200‑day, and volume is below average — factors that can amplify downside during negative headlines. Interactive Chart

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.